SCHEMBL17096845

SCHEMBL17096845

COCCNC(=O)c1n[nH]c2ccc(-c3cccc(F)c3F)cc12

nearest known ligand 0.78

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 12/20 0.78
WNT1 P04628 9/20 0.78
GSK3B P49841 8/20 0.68
KCNH2 Q12809 7/20 0.68
LYN P07948 1/20 0.68
GRK2 P25098 1/20 0.68
CLK1 P49759 1/20 0.68
GSK3A P49840 1/20 0.68
MAPK7 Q13164 1/20 0.68
DYRK2 Q92630 1/20 0.68
KDM4E B2RXH2 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17096017 0.88 DYRK1A (1.00) DYRK1AWNT1GSK3BKCNH2LYN
SCHEMBL17095647 0.87 DYRK1A (1.00) DYRK1AWNT1GSK3BKCNH2
SCHEMBL17095551 0.85 DYRK1A (1.00) DYRK1AWNT1GSK3BKCNH2
SCHEMBL30933964 0.84 DYRK1A (0.74) DYRK1AWNT1GSK3BKCNH2LYN
SCHEMBL21550495 0.84 DYRK1A (0.74) DYRK1AWNT1GSK3BKCNH2LYN
SCHEMBL17095560 0.83 DYRK1A (1.00) DYRK1AWNT1GSK3BKCNH2LYN
SCHEMBL17095852 0.83 DYRK1A (1.00) DYRK1AWNT1GSK3BKCNH2
SCHEMBL17095548 0.82 DYRK1A (1.00) DYRK1AWNT1GSK3BKCNH2LYN
SCHEMBL17095905 0.82 DYRK1A (0.80) DYRK1AWNT1GSK3BKCNH2LYN
SCHEMBL31061399 0.82 GSK3B (1.00) DYRK1AGSK3BKCNH2LYNGRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106535890-A 5-substituted indazole-3-carboxamides and preparation and use thereof 萨穆梅德有限公司 2017-03-22 CN claimed
EP-3119393-A1 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF Samumed, LLC (US) 2017-01-25 EP claimed
US-20150266825-A1 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2015-09-24 US claimed
WO-2015143380-A1 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF SAMUMED, LLC (US) 2015-09-24 WO claimed
US-10669240-B2 5-substituted indazole-3-carboxamides and preparation and use thereof SAMUMED, LLC (US) 2020-06-02 US disclosed
US-20180127377-A1 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2018-05-10 US disclosed
US-9745271-B2 5-substituted indazole-3-carboxamides and preparation and use thereof SAMUMED, LLC (US) 2017-08-29 US disclosed
US-20150266825-A1 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2015-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266825-A1 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF DYRK1A, WNT3, WNT1 DYRK1A 1/4885WNT1 3/4885GSK3B 7/4885
US-20180127377-A1 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF DYRK1A, WNT3, WNT1 DYRK1A 1/4885WNT1 3/4885GSK3B 7/4885
US-10669240-B2 5-substituted indazole-3-carboxamides and preparation and use thereof DYRK1A, WNT3, WNT1 DYRK1A 1/4885WNT1 3/4885GSK3B 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.